Unlocking The Efficacy of Tetrahydrobiopterin (BH4) Towards Metabolic Profile and Growth Status in Children with Phenylketonuria: A Meta Analysis
DOI:
https://doi.org/10.58427/apghn.4.3.2025.111-128Keywords:
BH4, children, growth status, metabolic profile, phenylketonuriaAbstract
Background: Phenylketonuria (PKU) is one of the most common types of inborn error of metabolism. Low-phenylalanine diet has been the main treatment for children with PKU. However, recent therapeutic alternatives have emerged as a solution in children with PKU in the form of tetrahydrobiopterin (BH4). This meta analysis aims to assess the effectiveness of BH4 in terms of response rate, metabolic profile and growth status.
Methods: Meta analysis was conducted by searching databases such as PubMed, ScienceDirect, Cochrane Library, medRxiv, and Scopus based on the Preferred Reporting Items for Systematic Reviews and Meta Analysis (PRISMA) guidelines. Data synthesis and analyses were conducted using R version 4.5.1 (R Foundation for Statistical Computing).
Result: Fifteen studies were involved in this research, consisting of 1280 children (1063 given BH4). Eight studies reported BH4 reduced plasma phenylalanine concentration by around (686.83 mg/day [95% CI 394.85 to 978.82], p <0.001). Additionally, two studies reported a reduction in plasma phenylalanine concentration, measured in mg/kg/day, following BH4 administration. Children given BH4 and low phenylalanine diet combination showed a higher response rate compared to BH4 only (100% vs 76%). Two studies showed no difference in growth outcomes, which remained within the normal range.
Conclusion: BH4 shows promise as an adjunct therapy for children with PKU, but confirmation through larger, standardized, long-term studies assessing outcomes such as growth status and long-term neurocognitive outcome is needed.
References
Blau N, van Spronsen FJ, Levy HL. Phenylketonuria. Lancet. 2010;376(9750):1417-27. https://doi.org/10.1016/s0140-6736(10)60961-0 DOI: https://doi.org/10.1016/S0140-6736(10)60961-0
Vockley J, Andersson HC, Antshel KM, Braverman NE, Burton BK, Frazier DM, et al. Phenylalanine hydroxylase deficiency: Diagnosis and management guideline. Genet Med. 2014;16(2):188-200. https://doi.org/10.1038/gim.2013.157 DOI: https://doi.org/10.1038/gim.2013.157
Arnold G, Vockley J. Phenylalanine hydroxylase deficiency. Seattle University of Washington; 2025.
Qu J, Yang T, Wang E, Li M, Chen C, Ma L, et al. Efficacy and safety of sapropterin dihydrochloride in patients with phenylketonuria: A meta-analysis of randomized controlled trials. Br J Clin Pharmacol. 2019;85(5):893-9. https://doi.org/10.1111/bcp.13886 DOI: https://doi.org/10.1111/bcp.13886
Levy HL, Milanowski A, Chakrapani A, Cleary M, Lee P, Trefz FK, et al. Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6r-bh4) for reduction of phenylalanine concentration in patients with phenylketonuria: A phase iii randomised placebo-controlled study. Lancet. 2007;370(9586):504-10. https://doi.org/10.1016/s0140-6736(07)61234-3 DOI: https://doi.org/10.1016/S0140-6736(07)61234-3
Tansek MZ, Groselj U, Murko S, Kobe H, Lampret BR, Battelino T. Assessment of tetrahydrobiopterin (bh(4))-responsiveness and spontaneous phenylalanine reduction in a phenylalanine hydroxylase deficiency population. Mol Genet Metab. 2012;107(1-2):37-42. https://doi.org/10.1016/j.ymgme.2012.07.010 DOI: https://doi.org/10.1016/j.ymgme.2012.07.010
Trefz FK, Scheible D, Frauendienst-Egger G. Long-term follow-up of patients with phenylketonuria receiving tetrahydrobiopterin treatment. J Inherit Metab Dis. 2010;33 Suppl 3:S163-9. https://doi.org/10.1007/s10545-010-9058-x DOI: https://doi.org/10.1007/s10545-010-9058-x
Feillet F, Arnoux JB, Delgado MB, Burlina A, Chabrol B, Kucuksayrac E, et al. Long-term safety of sapropterin in paediatric and adult individuals with phenylalanine hydroxylase deficiency: Final results of the kuvan® adult maternal paediatric european registry multinational observational study. J Inherit Metab Dis. 2025;48(1):e12796. https://doi.org/10.1002/jimd.12796 DOI: https://doi.org/10.1002/jimd.12796
Muntau AC, Burlina A, Eyskens F, Freisinger P, De Laet C, Leuzzi V, et al. Efficacy, safety and population pharmacokinetics of sapropterin in pku patients <4 years: Results from the spark open-label, multicentre, randomized phase iiib trial. Orphanet J Rare Dis. 2017;12(1):47. https://doi.org/10.1186/s13023-017-0600-x DOI: https://doi.org/10.1186/s13023-017-0600-x
Muntau AC, Burlina A, Eyskens F, Freisinger P, Leuzzi V, Sivri HS, et al. Long-term efficacy and safety of sapropterin in patients who initiated sapropterin at < 4 years of age with phenylketonuria: Results of the 3-year extension of the spark open-label, multicentre, randomised phase iiib trial. Orphanet J Rare Dis. 2021;16(1):341. https://doi.org/10.1186/s13023-021-01968-1 DOI: https://doi.org/10.1186/s13023-021-01968-1
Fiege B, Blau N. Assessment of tetrahydrobiopterin (bh4) responsiveness in phenylketonuria. J Pediatr. 2007;150(6):627-30. https://doi.org/10.1016/j.jpeds.2007.02.017 DOI: https://doi.org/10.1016/j.jpeds.2007.02.017
Kör D, Yılmaz B, Bulut FD, Ceylaner S, Mungan N. Improved metabolic control in tetrahydrobiopterin (bh4), responsive phenylketonuria with sapropterin administered in two divided doses vs. A single daily dose. J Pediatr Endocrinol Metab. 2017;30(7):713-8. https://doi.org/10.1515/jpem-2016-0461 DOI: https://doi.org/10.1515/jpem-2016-0461
Eshraghi P, Noroozi Asl S, Bagheri S, Chalak V. Response to sapropterin hydrochloride (kuvan®) in children with phenylketonuria (pku): A clinical trial. J Pediatr Endocrinol Metab. 2019;32(8):885-8. https://doi.org/10.1515/jpem-2018-0503 DOI: https://doi.org/10.1515/jpem-2018-0503
Hennermann JB, Bührer C, Blau N, Vetter B, Mönch E. Long-term treatment with tetrahydrobiopterin increases phenylalanine tolerance in children with severe phenotype of phenylketonuria. Mol Genet Metab. 2005;86 Suppl 1:S86-90. https://doi.org/10.1016/j.ymgme.2005.05.013 DOI: https://doi.org/10.1016/j.ymgme.2005.05.013
Brantley KD, Douglas TD, Singh RH. One-year follow-up of b vitamin and iron status in patients with phenylketonuria provided tetrahydrobiopterin (bh4). Orphanet J Rare Dis. 2018;13(1):192. https://doi.org/10.1186/s13023-018-0923-2 DOI: https://doi.org/10.1186/s13023-018-0923-2
Aldámiz-Echevarría L, Bueno MA, Couce ML, Lage S, Dalmau J, Vitoria I, et al. 6r-tetrahydrobiopterin treated pku patients below 4 years of age: Physical outcomes, nutrition and genotype. Mol Genet Metab. 2015;115(1):10-6. https://doi.org/10.1016/j.ymgme.2015.03.007 DOI: https://doi.org/10.1016/j.ymgme.2015.03.007
Aldámiz-Echevarría L, Bueno MA, Couce ML, Lage S, Dalmau J, Vitoria I, et al. Tetrahydrobiopterin therapy vs phenylalanine-restricted diet: Impact on growth in pku. Mol Genet Metab. 2013;109(4):331-8. https://doi.org/10.1016/j.ymgme.2013.05.017 DOI: https://doi.org/10.1016/j.ymgme.2013.05.017
Longo N, Siriwardena K, Feigenbaum A, Dimmock D, Burton BK, Stockler S, et al. Long-term developmental progression in infants and young children taking sapropterin for phenylketonuria: A two-year analysis of safety and efficacy. Genet Med. 2015;17(5):365-73. https://doi.org/10.1038/gim.2014.109 DOI: https://doi.org/10.1038/gim.2014.109
Ziesch B, Weigel J, Thiele A, Mütze U, Rohde C, Ceglarek U, et al. Tetrahydrobiopterin (bh4) in pku: Effect on dietary treatment, metabolic control, and quality of life. J Inherit Metab Dis. 2012;35(6):983-92. https://doi.org/10.1007/s10545-012-9458-1 DOI: https://doi.org/10.1007/s10545-012-9458-1
Tansek MZ, Groselj U, Kelvisar M, Kobe H, Lampret BR, Battelino T. Long-term bh4 (sapropterin) treatment of children with hyperphenylalaninemia - effect on median phe/tyr ratios. J Pediatr Endocrinol Metab. 2016;29(5):561-6. https://doi.org/10.1515/jpem-2015-0337 DOI: https://doi.org/10.1515/jpem-2015-0337
Lee P, Treacy EP, Crombez E, Wasserstein M, Waber L, Wolff J, et al. Safety and efficacy of 22 weeks of treatment with sapropterin dihydrochloride in patients with phenylketonuria. Am J Med Genet A. 2008;146a(22):2851-9. https://doi.org/10.1002/ajmg.a.32562 DOI: https://doi.org/10.1002/ajmg.a.32562
Bélanger-Quintana A, Burlina A, Harding CO, Muntau AC. Up to date knowledge on different treatment strategies for phenylketonuria. Mol Genet Metab. 2011;104 Suppl(0):S19-25. https://doi.org/10.1016/j.ymgme.2011.08.009 DOI: https://doi.org/10.1016/j.ymgme.2011.08.009
MacDonald A, van Wegberg AMJ, Ahring K, Beblo S, Bélanger-Quintana A, Burlina A, et al. Pku dietary handbook to accompany pku guidelines. Orphanet J Rare Dis. 2020;15(1):171. https://doi.org/10.1186/s13023-020-01391-y DOI: https://doi.org/10.1186/s13023-020-01391-y
Lammardo AM, Robert M, Rocha JC, van Rijn M, Ahring K, Bélanger-Quintana A, et al. Main issues in micronutrient supplementation in phenylketonuria. Mol Genet Metab. 2013;110 Suppl:S1-5. https://doi.org/10.1016/j.ymgme.2013.08.008 DOI: https://doi.org/10.1016/j.ymgme.2013.08.008
Demirdas S, van Spronsen FJ, Hollak CEM, van der Lee JH, Bisschop PH, Vaz FM, et al. Micronutrients, essential fatty acids and bone health in phenylketonuria. Ann Nutr Metab. 2017;70(2):111-21. https://doi.org/10.1159/000465529 DOI: https://doi.org/10.1159/000465529
MacLeod EL, Gleason ST, van Calcar SC, Ney DM. Reassessment of phenylalanine tolerance in adults with phenylketonuria is needed as body mass changes. Mol Genet Metab. 2009;98(4):331-7. https://doi.org/10.1016/j.ymgme.2009.07.016 DOI: https://doi.org/10.1016/j.ymgme.2009.07.016
Thöny B, Ding Z, Martínez A. Tetrahydrobiopterin protects phenylalanine hydroxylase activity in vivo: Implications for tetrahydrobiopterin-responsive hyperphenylalaninemia. FEBS Lett. 2004;577(3):507-11. https://doi.org/10.1016/j.febslet.2004.10.056 DOI: https://doi.org/10.1016/j.febslet.2004.10.056
Gersting SW, Lagler FB, Eichinger A, Kemter KF, Danecka MK, Messing DD, et al. Pahenu1 is a mouse model for tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency and promotes analysis of the pharmacological chaperone mechanism in vivo. Hum Mol Genet. 2010;19(10):2039-49. https://doi.org/10.1093/hmg/ddq085 DOI: https://doi.org/10.1093/hmg/ddq085
Ilgaz F, Marsaux C, Pinto A, Singh R, Rohde C, Karabulut E, et al. Protein substitute requirements of patients with phenylketonuria on bh4 treatment: A systematic review and meta-analysis. Nutrients. 2021;13(3). https://doi.org/10.3390/nu13031040 DOI: https://doi.org/10.3390/nu13031040
Published
Issue
Section
License
Copyright (c) 2025 Rafi Alfian Razan, Nur Aisiyah Widjaja, Anggie Lorenza, Vianca Samara Andhary, Naoval Diza Ananda
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
